The $360 Billion Market that Medicine Got Wrong for 20 Years

The women’s health market (~$360B) is seeing renewed momentum in menopause care, supported by the FDA rolling back longstanding HRT warnings. Venture activity and newer entrants (e.g., Stripes, Midi Health) alongside investors like Amboy Street Ventures signal growing commercial interest, though the article flags a risk of consumers being misled by unproven “wellness” products versus evidence-based treatment. Overall, the regulatory shift is a positive catalyst, but near-term market impact is likely more thematic than immediate for public earnings.

Analysis

This is less a single-product story than a reimbursement and distribution shift. The equity upside accrues to businesses that can convert latent demand into paid prescriptions or covered benefits; the losers are unregulated wellness brands that depend on ambiguity and discretionary spend. The biggest second-order effect is that employers may start treating midlife women’s health as a productivity line item, which is far more durable than consumer buzz and could shift budgets toward telehealth, primary care, and pharmacy channels.

The timing matters: the near-term reaction can be driven by narrative, but the revenue impact is a 2-3 quarter claims-data story. If payer coverage widens and clinicians get more comfortable, the best operating leverage sits with names that already have distribution and prescription workflows rather than pure-theme DTC concepts. On the other hand, if utilization does not show up in scripts, the market will quickly de-rate this as another wellness category with weak repeat economics.

The contrarian point is that the market may be underestimating the size of the funnel but overestimating the cleanliness of the equity expression. Evidence-based care should win share from supplements, but public equities are only a partial proxy, so investors may pay up for a theme without a direct earnings bridge. Falsifier: no measurable increase in prescription volume, employer benefit adoption, or guidance commentary over the next two earnings cycles.

Key Decisions for Investors

• Initiate a small tactical long in OGN over the next 1-2 weeks as the cleanest public-market beneficiary of broader hormone-therapy normalization; target a 3-6 month hold. Risk/reward is attractive only if prescription trends inflect; cut if there is no evidence of script growth by the next two quarters.
• Use WWRL only as a small thematic basket position, not a core holding. The upside is a gradual rerating over 6-12 months if women’s midlife health becomes an employer-covered category, but the trade should stay small because the monetization path is indirect.
• If you want higher-beta exposure, buy HIMS on pullbacks as a consumer-distribution proxy for women’s health expansion, but keep size modest. Thesis works if the company can add menopause-related care without CAC inflation; invalidate if growth or margins do not improve in the next 1-2 earnings prints.
• Avoid chasing unprofitable wellness/discretionary-health names on the narrative alone. The market is likely to overpay for marketing-driven menopause stories before there is any claims or reimbursement evidence.